Literature DB >> 29532102

Is it time to change our vision of tumor metabolism prior to immunotherapy?

Fabio Grizzi1, Angelo Castello2, Egesta Lopci3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29532102     DOI： 10.1007/s00259-018-3988-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis.

Authors:  Egesta Lopci; Fabio Grizzi; Carlo Russo; Luca Toschi; Ilaria Grassi; Gianfranco Cicoria; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Nucl Med Commun       Date:  2017-04       Impact factor: 1.690

2.  Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.

Authors:  Gouji Toyokawa; Kazuki Takada; Tatsuro Okamoto; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Takaki Akamine; Shinkichi Takamori; Masakazu Katsura; Fumihiro Shoji; Ryuji Hamamoto; Yoshinao Oda; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2017-03       Impact factor: 2.480

Review 3.  The Warburg effect then and now: from cancer to inflammatory diseases.

Authors:  Eva M Palsson-McDermott; Luke A J O'Neill
Journal:  Bioessays       Date:  2013-09-20       Impact factor: 4.345

4.  Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer.

Authors:  Zachary D Horne; Robert Jack; Zachary T Gray; Jill M Siegfried; David O Wilson; Samuel A Yousem; Katie S Nason; Rodney J Landreneau; James D Luketich; Matthew J Schuchert
Journal:  J Surg Res       Date:  2011-04-22       Impact factor: 2.192

5.  Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Authors:  Egesta Lopci; Luca Toschi; Fabio Grizzi; Daoud Rahal; Laura Olivari; Giovanni Francesco Castino; Silvia Marchetti; Nina Cortese; Dorina Qehajaj; Daniela Pistillo; Marco Alloisio; Massimo Roncalli; Paola Allavena; Armando Santoro; Federica Marchesi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-01       Impact factor: 9.236

6.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 7.  Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jing Liu; Min Dong; Xiaorong Sun; Wenwu Li; Ligang Xing; Jinming Yu
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

8.  Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.

Authors:  Mohammad Rashidian; Jessica R Ingram; Michael Dougan; Anushka Dongre; Katherine A Whang; Camille LeGall; Juan J Cragnolini; Brian Bierie; Monica Gostissa; James Gorman; Gijsbert M Grotenbreg; Atul Bhan; Robert A Weinberg; Hidde L Ploegh
Journal:  J Exp Med       Date:  2017-06-30       Impact factor: 14.307

9.  Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Kazuki Takada; Gouji Toyokawa; Tatsuro Okamoto; Shingo Baba; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Takaki Akamine; Shinkichi Takamori; Masakazu Katsura; Fumihiro Shoji; Hiroshi Honda; Yoshinao Oda; Yoshihiko Maehara
Journal:  Cancer Med       Date:  2017-10-04       Impact factor: 4.452
  9 in total
  20 in total

1.  The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT.

Authors:  Laura Evangelista
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

2.  Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?

Authors:  Nicolas Aide; Michel De Pontdeville; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05       Impact factor: 9.236

3.  Radiopharmaceuticals as Novel Immune System Tracers.

Authors:  Natalie A Ridge; Anne Rajkumar-Calkins; Stephanie O Dudzinski; Austin N Kirschner; Neil B Newman
Journal:  Adv Radiat Oncol       Date:  2022-06-18

4.  Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.

Authors:  Francesca Castagnoli; Simon Doran; Jason Lunn; Anna Minchom; Mary O'Brien; Sanjay Popat; Christina Messiou; Dow-Mu Koh
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

5.  The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.

Authors:  Angelo Castello; Luca Toschi; Sabrina Rossi; Emanuela Mazziotti; Egesta Lopci
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-11       Impact factor: 4.553

6.  Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.

Authors:  Romain-David Seban; Laura Mezquita; Arnaud Berenbaum; Laurent Dercle; Angela Botticella; Cécile Le Pechoux; Caroline Caramella; Eric Deutsch; Serena Grimaldi; Julien Adam; Samy Ammari; David Planchard; Sophie Leboulleux; Benjamin Besse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-21       Impact factor: 9.236

Review 7.  Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.

Authors:  Stefano Frega; Alessandro Dal Maso; Giulia Pasello; Lea Cuppari; Laura Bonanno; PierFranco Conte; Laura Evangelista
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

8.  Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study.

Authors:  Linping Ke; Lu Wang; Jinming Yu; Xue Meng
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

Review 9.  FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Authors:  Nicolas Aide; Rodney J Hicks; Christophe Le Tourneau; Stéphanie Lheureux; Stefano Fanti; Egesta Lopci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-05       Impact factor: 9.236

10.  The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.

Authors:  Xiuli Tao; Ning Li; Ning Wu; Jie He; Jianming Ying; Shugeng Gao; Shuhang Wang; Jie Wang; Zhijie Wang; Yun Ling; Wei Tang; Zewei Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-11       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.